For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
One new case of COVID-19
One new case of COVID-19

There is one new case of COVID-19 to report in managed isolation in New Zealand today.
It has been 78 days since the last case of COVID-19 was acquired locally from an unknown source.
Today’s case is a man in his 50s who arrived in New Zealand on July 12 from Central Africa via Tanzania, Doha and Brisbane. He is now in the quarantine facility in Auckland after being transferred yesterday.
The number of active cases in New Zealand is 22.
The total number of confirmed cases of COVID-19 is now 1,200, which is the number we report to the World Health Organization.
There is no one in New Zealand receiving hospital-level care for COVID-19.
Yesterday our laboratories completed 2,403 tests.
The total number of tests completed in New Zealand to date is 441,123.